What to Look For When Perrigo (PRGO) Reports Q1 Results
NEW YORK (TheStreet) -- Perrigo (PRGO) - Get Report shares are sliding 1.05% to $92.09 on Wednesday afternoon despite expectations of both profit and revenue rising year-over-year.
The company is scheduled to release its 2016 first quarter earnings on Thursday before the market open.
Wall Street is looking for earnings of $1.75 a share on revenue of $1.35 billion.
A year ago, the company earned $1.74 a share on revenue of $1.14 billion.
Despite the earnings growth, Goldman Sachs analysts predict several challenges, including prescription-business pricing pressure and fewer product launches.
Based in Dublin, Perrigo develops, manufactures, markets, and distributes over-the-counter (OTC) consumer goods and pharmaceutical products worldwide.
Separately, TheStreet Ratings currently has a "Hold" rating on the stock with a letter grade of C-.
The company's strengths can be seen in multiple areas, such as its robust revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow.
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.
You can view the full analysis from the report here: PRGO
